Advancing Neurological and Retinal Research with Genetically Diverse Human iPSC-Derived Models
In this webinar, Andrew Gaffney, Director of Stem Cell Manufacturing and Commercialization at º£½ÇÆƽâ°æ Technologies, showcases how high-quality, genetically diverse iPSC lines and differentiated cells are advancing research in neurological and retinal diseases. Manufactured to meet ISSCR standards, these iPSC lines undergo extensive quality control, ensuring consistency and reliability for disease modeling and drug discovery. º£½ÇÆƽâ°æ has optimized the differentiation of these iPSCs into mature, functional astrocytes and retinal pigment epithelial (RPE) cells that exhibit hallmark physiological behaviors.
As a supporter of, and participant in, ISSCR’s 2025 Annual Meeting, we share with you our presentation at ISSCR 2025. This presentation does not represent an endorsement from or support of the ISSCR.
In this webinar, Andrew Gaffney, Director of Stem Cell Manufacturing and Commercialization at º£½ÇÆƽâ°æ Technologies, showcases how high-quality, genetically diverse iPSC lines and differentiated cells are advancing research in neurological and retinal diseases. Manufactured to meet ISSCR standards, these iPSC lines undergo extensive quality control, ensuring consistency and reliability for disease modeling and drug discovery. Andrew outlines how these healthy control lines demonstrate strong pluripotency and genetic stability and are compatible with a range of STEMdiffâ„¢ differentiation kits.
Through validated workflows, º£½ÇÆƽâ°æ has optimized the differentiation of these iPSCs into mature, functional astrocytes and retinal pigment epithelial (RPE) cells that exhibit hallmark physiological behaviors. Astrocytes generated from SCTi003-A iPSCs show glutamate uptake, inflammatory responsiveness, and compatibility in co- and tri-culture systems, making them ideal for neurological modeling applications. Resulting RPE cells demonstrate robust maturation, tight barrier formation, and polarized secretion. Andrew also introduces an ABCA4 knockout RPE model that replicates Stargardt disease pathology, including impaired photoreceptor outer segment digestion and lipid accumulation.
As a supporter of, and participant in, ISSCR’s 2025 Annual Meeting, we share with you our presentation at ISSCR 2025. This presentation does not represent an endorsement from or support of the ISSCR.
Through validated workflows, º£½ÇÆƽâ°æ has optimized the differentiation of these iPSCs into mature, functional astrocytes and retinal pigment epithelial (RPE) cells that exhibit hallmark physiological behaviors. Astrocytes generated from SCTi003-A iPSCs show glutamate uptake, inflammatory responsiveness, and compatibility in co- and tri-culture systems, making them ideal for neurological modeling applications. Resulting RPE cells demonstrate robust maturation, tight barrier formation, and polarized secretion. Andrew also introduces an ABCA4 knockout RPE model that replicates Stargardt disease pathology, including impaired photoreceptor outer segment digestion and lipid accumulation.
As a supporter of, and participant in, ISSCR’s 2025 Annual Meeting, we share with you our presentation at ISSCR 2025. This presentation does not represent an endorsement from or support of the ISSCR.
Publish Date:
August 04, 2025
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to º£½ÇÆƽâ°æ Technologies Canada Inc. and its subsidiaries and affiliates (“º£½ÇÆƽâ°æâ€) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
Related Multimedia
-
Best Practice Criteria for Pluripotent Stem Cell Lines
Publish Date: April 20, 2020 -
Highly Characterized Human iPSCs and NPCs for Downstream Differentiation Applications
Publish Date: July 19, 2023 -
Development of iPSCs, Differentiated Cells, and Organoids Under Stringent Quality Standards
Publish Date: July 31, 2023
Explore Our Products
-
cGMP, stabilized feeder-free maintenance medium for human ES and iPS cells -
Cell detachment solution -
Healthy Control Human iPSC Line, Female, SCTi003-A
Human pluripotent stem cell line, frozen -
STEMdiffâ„¢ Astrocyte Differentiation Kit
Serum-free differentiation kit for generating astrocyte precursors from hPSC-derived neural progenitor cells
